United States Food and Drug Administration (USFDA) has completed inspection at Ind-Swift Laboratories’ API manufacturing facility at Derabassi (Punjab), near Chandigarh, India, which was conducted from March 9, 2020 to March 13, 2020. The USFDA has cleared this inspection without any 483 observation.
The Derabassi API manufacturing facility of the company, which has 22 Independent manufacturing blocks, is one of the largest manufacturing facility of Northern India, with annual manufacturing capacity of 695 tonnes per annum.
Ind-Swift Laboratories is engaged in the manufacture of Active Pharmaceutical Ingredients (API). The product range of the company includes Macrolide antibiotics, Cardiovascular, Anti histamine, Anti diabetic, Analgesic, Aromatase inhibtors, Anti depressant,Alcohol absistence, etc.
